NTRK Gene Fusions

A new pan-cancer companion diagnostic indication has been added to the TruSight Oncology Comprehensive test, which will help identify patients who may benefit from targeted therapy with larotrectinib.

The FoundationOne CDx has been granted approval by the FDA to identify patients with ROS1 fusion–positive non–small cell lung cancer or NTRK fusion–positive cancers who might be candidates for entrectinib.

Alexander Drilon, MD, discussed NTRK gene fusions in solid tumors, collective findings of studies assessing larotrectinib for the treatment of these fusions, and how to conduct genomic testing to identify patients who might benefit from TRK inhibitor therapy.

In the interview with Targeted Oncology, Marcia S. Brose, MD, PhD, FASCO discussed treatment of TRK fusion-positive thyroid cancer based on the most recent data from 2022 ASCO Annual Meeting and ongoing studies.

Orphan drug designation has been granted by the FDA to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors, including primary and metastatic brain tumors.

Lori J. Wirth, MD, explains the role of NTRK inhibitor in TRK fusion-positive thyroid cancer treatment.

Lori J. Wirth, MD, discusses a new assay with the ability to perform DNA and RNA sequencing to better detect gene fusions.

In an interview with Targeted Oncology, Lori Wirth, MD, discussed the evolving treatment landscape for NTRK fusion-positive thyroid cancers.

David S. Hong, MD, discusses the data supporting the use of larotrectinib for the treatment of TRK fusion-positive lung tumors. He also explains the difference between larotrectinib another FDA-approved TRK inhibitor, entrectinib.